GeoVax Labs (NASDAQ:GOVX) Announces Quarterly Earnings Results

GeoVax Labs (NASDAQ:GOVX) announced its quarterly earnings data on Thursday. The company reported ($10.56) earnings per share for the quarter, topping the consensus estimate of ($26.16) by $15.60, FiscalAI reports.

GeoVax Labs Stock Performance

Shares of GeoVax Labs stock traded down $0.12 on Thursday, reaching $2.04. The stock had a trading volume of 125,927 shares, compared to its average volume of 42,020. The stock has a market cap of $632,400.00, a P/E ratio of -0.18 and a beta of 3.85. The business’s 50-day moving average price is $6.91 and its two-hundred day moving average price is $27.58. GeoVax Labs has a fifty-two week low of $1.84 and a fifty-two week high of $300.00.

Analyst Ratings Changes

GOVX has been the topic of several recent research reports. Noble Financial restated an “outperform” rating on shares of GeoVax Labs in a report on Tuesday, September 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $3,600.00.

About GeoVax Labs

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer. The company’s technology platform is based primarily on modified vaccinia Ankara (MVA) and virus-like particle (VLP) vaccine technologies, which are designed to generate broad and durable immune responses. GeoVax’s pipeline has included GEO-CM04S1, a multivalent COVID-19 vaccine candidate intended to address emerging coronavirus variants, as well as investigational vaccines for HIV, hemorrhagic fever viruses such as Ebola and Marburg, and other infectious diseases.